Carlsbad, California, USA, September 17, 2026
Aptitude Medical Systems has announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its next-generation Metrix® COVID-19 Test, expanding the company’s portfolio of rapid molecular diagnostic technologies for detecting SARS-CoV-2. The FDA clearance represents an important regulatory milestone for Aptitude and supports the use of its molecular testing platform in the United States. The Metrix system is designed to provide rapid, highly sensitive molecular detection of COVID-19, combining laboratory-grade molecular testing technology with a compact platform intended for use closer to the patient. The company said the next-generation test incorporates improvements intended to enhance usability and testing performance while maintaining the advantages of molecular diagnostics.
FDA Clearance Advances Rapid Molecular Testing
The newly cleared Metrix COVID-19 Test uses molecular amplification technology to detect genetic material from SARS-CoV-2, the virus responsible for COVID-19. Molecular tests are designed to identify viral nucleic acid and can provide high analytical sensitivity compared with many antigen-based approaches. Aptitude developed the Metrix platform to bring molecular testing capabilities into decentralized environments, potentially allowing testing to be performed outside conventional centralized laboratories. The FDA 510(k) clearance indicates that the agency determined the device to be substantially equivalent to a legally marketed predicate device for its intended use. This regulatory pathway is commonly used for medical devices, including diagnostic tests, when manufacturers can demonstrate that a new device is sufficiently comparable in safety and effectiveness to an existing legally marketed device. The clearance provides Aptitude with an important regulatory foundation for expanding availability of its next-generation COVID-19 diagnostic technology in the U.S. market.
The company has positioned Metrix as a platform designed to deliver molecular results rapidly while reducing some of the infrastructure requirements associated with conventional laboratory testing. This approach may be particularly relevant for point-of-care and decentralized diagnostic settings, where healthcare professionals need timely information to support clinical decision-making.
Metrix Platform Combines Speed and Molecular Detection
Advertisement
A key feature of the Metrix system is its compact molecular testing architecture. Rather than requiring samples to be transported to a centralized laboratory, the platform is designed to enable testing closer to where patients receive care. Aptitude’s technology is intended to combine the sensitivity associated with molecular amplification with a workflow that can be used in a range of healthcare environments. The next-generation COVID test is designed to detect SARS-CoV-2 viral RNA from appropriate patient specimens. Rapid access to molecular diagnostic information can help healthcare providers make more informed decisions about patient management, infection-control measures and the need for additional evaluation. While COVID-19 remains an evolving infectious disease, diagnostic testing continues to play a role in identifying active infections and supporting appropriate clinical care.
Aptitude’s broader Metrix platform also reflects the company’s strategy of developing molecular diagnostic technologies that can be adapted to multiple infectious diseases. The company has previously worked on molecular testing applications beyond SARS-CoV-2, highlighting the potential for a common diagnostic platform to support testing across different pathogens.
Expanding Access to Decentralized Diagnostics
The FDA clearance comes as the diagnostics industry continues to focus on rapid, decentralized molecular testing. Conventional molecular diagnostics can require specialized laboratory equipment, trained personnel and centralized workflows, potentially increasing the time between sample collection and results. Compact molecular platforms seek to shorten that process by bringing testing capabilities directly into healthcare settings. For Aptitude, the regulatory milestone strengthens the company’s position in the point-of-care molecular diagnostics market. The next-generation Metrix COVID-19 Test could provide healthcare organizations with another FDA-cleared option for molecular SARS-CoV-2 testing while supporting the company’s continued development of its diagnostic platform.
The clearance also demonstrates the continuing evolution of COVID-19 diagnostic technology, from large centralized laboratory systems toward smaller and more accessible molecular platforms. As infectious-disease testing requirements evolve, technologies that can deliver timely molecular information in decentralized settings may remain an important component of modern diagnostic infrastructure. With the FDA 510(k) clearance secured, Aptitude can move forward with the U.S. commercialization of its next-generation Metrix COVID-19 Test, subject to applicable regulatory and commercial requirements. The development represents another step toward expanding access to rapid molecular diagnostics and demonstrates the ongoing role of medical technology innovation in infectious-disease detection.
Source: Aptitude Medical Systems press release
